-
Talphera reaches 17-patient enrollment in NEPHRO CRRT pivotal trial
-
H.C. Wainwright Reiterates Buy Rating on Talphera (TLPH)
-
Talphera (TLPH) Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement
-
Rodman & Renshaw Starts Talphera (TLPH) at Buy
-
Talphera (TLPH) Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
-
Talphera (TLPH) Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

